Traws Pharma Stock Drops 17% After UK Regulator Delays Flu Drug Trial 

One regulatory hold is a setback. Two is a pattern, and Traws Pharma is now facing exactly that. On June 12, 2026, Traws Pharma (NASDAQ: TRAW) announced that its planned Phase 2a human influenza challenge study of tivoxavir marboxil (TXM) has been deferred following a negative review by the UK’s Medicines and Healthcare Products Regulatory Agency. 

The stock fell 17% in premarket trading on Monday. It compounding a 28% after-hours collapse on Friday when the news first broke. Both regulatory rejections center on the same concern: mutagenicity, the potential of the compound to cause genetic mutations, which has now blocked TXM’s clinical path in both the US and UK simultaneously. 

The Regulatory Timeline: How Two Countries Blocked the Same Drug

The MHRA’s action did not arrive without warning. The FDA had already moved first.

• In February 2026, the FDA placed a clinical hold on Traws Pharma’s investigational new drug (IND) application for tivoxavir marboxil. It citing concerns with the mutagenicity data package. 
• The FDA was expected to formally communicate its concerns alongside suggested mitigation steps by March 16, 2026; the clinical hold did not directly impact studies outside the US at that time. 
• The Phase 2a study in the UK, which was slated to begin this quarter. It involved healthy volunteers receiving either TXM or a placebo before being exposed to a controlled influenza strain in a human challenge model. 
• Traws Pharma confirmed it is stepping back from the MHRA study while actively working on backup drug candidates. It maintain TXM’s long-acting antiviral profile but eliminate any mutagenic potential.

What Tivoxavir Marboxil Actually Is — and Why It Still Has Value

The Science Beneath the Regulatory Setback

Tivoxavir marboxil demonstrated potent efficacy in three animal models of highly pathogenic avian influenza, with a pharmacokinetic profile consistent with both bird flu treatment and prevention use cases. The compound was being positioned for two distinct applications simultaneously. 

• TXM was filed with the FDA’s BARDA for potential inclusion in the US strategic stockpile for avian influenza treatment. This is a government procurement path that operates independently of standard commercial clinical trial timelines. 
• Preclinical tablet data showed modelling that suggested 28-day protection from a single oral dose, positioning TXM as a potential once-monthly influenza prophylaxis candidate. 
• CMO Robert R. Redfield, former director of the US Centers for Disease Control and Prevention, stated: “While we have had a setback in the development of our lead compound for influenza, the program continues to be a high priority.”
• A shelf registration filed on May 8, 2026, covers up to 35,897,514 common shares for resale by existing holders, a dilution overhang that adds selling pressure on top of the regulatory news. 

Cash Runway and What Comes Next for Traws Pharma

Traws Pharma holds a cash runway extending into Q1 2027. It supported by a private financing arrangement of up to $60 million comprising $10 million upfront and milestone-based warrants. That runway gives the company time to advance its backup program without immediately returning to capital markets. Beyond influenza, Traws Pharma has expanded its antiviral pipeline into adjacent high-risk areas. 

On May 27, 2026, the company announced a new antiviral program targeting Hantavirus and Ebola Virus Disease outbreaks. Both classified as emergency-use development priorities. Peer clinical-stage antiviral names, including Vir Biotechnology (NASDAQ: VIR) and Roche, both active in influenza and pandemic preparedness. It operate in the same regulatory environment where mutagenicity data requirements have grown increasingly stringent.

Final Thoughts

Traws Pharma’s double regulatory rejection is not a verdict on the science. It is a verdict on the safety data package. TXM’s antiviral efficacy across three animal models of avian influenza remains intact. The company retains a portfolio of backup compounds and a pipeline now expanding into Hantavirus and Ebola.

The cash runway into Q1 2027 provides a meaningful window to address the mutagenicity concerns formally, but the timeline for re-entering clinical study in either the US or UK now stretches well beyond 2026. The stock’s 17% premarket drop is the market pricing that delay in real time.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.